MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2019 International Congress

    Cognitive Processes That Indirectly Effect Olfactory Dysfunction in Parkinson’s Disease

    B. Chase, A. Mertens, J. Santo, K. Markopoulou (Omaha, NE, USA)

    Objective: Investigate cognitive mechanisms contributing to olfactory dysfunction in Parkinson’s disease. Background: Accurate early diagnosis of Parkinson’s disease is hampered by its long prodromal period…
  • 2019 International Congress

    Levodopa/carbidopa Intestinal Gel in Treatment of Non-Motor Symptoms in Advanced Parkinson’s Disease

    W. Kamel, J. Al Hashel (Beni Suef, Egypt)

    Objective: To identify the advantages of LCIG in the treatment of NMS among APD patients and appraise the currently available literature to identify the gaps…
  • 2019 International Congress

    Postural and kinetic tremor is associated with pallidal dopamine denervation in patients with Parkinson’s disease

    N. Choi, KW. Park, SH. Hong, CS. Lee (Seoul, Republic of Korea)

    Objective: To investigate the role of dopamine denervation in the globus pallidus in PD patients with postural and kinetic tremor (PT/KT) in Parkinson’s disease(PD) using…
  • 2019 International Congress

    Role of clinical neuroimaging in X-linked dystonia-parkinsonism

    J. Junker, A. Neumann, R. Rosales, D. Jamora, C. Diesta, J. Prasuhn, T. Muente, C. Klein, P. Schramm, N. Brueggemann (Luebeck, Germany)

    Objective: To determine the inter- and intra-rater reliability of brain imaging in X-linked dystonia-parkinsonism (XDP). Background: XDP is a neurodegenerative movement disorder presenting with adult-onset…
  • 2019 International Congress

    FDG PET: a good predictive tool for CNS inflammation

    M. Nader, F. Fluchere, T. Witjas, A. Eusebio, JP. Azulay (Marseille, France)

    Objective: 1)When to suspect an underlying autoimmune process in patients presenting with parkinsonism. 2)To highlight the importance of FDG PET as a complementary exam in…
  • 2019 International Congress

    Appropriateness of DAT Scan Ordering in a University Hospital Practice

    Z. Togher, S. Fullam, J. Britton, J. Duignan, R. Killeen, S. O'Riordan, M. Hutchinson (Dublin 4, Ireland)

    Objective: To examine the diagnostic utility (or misuse) of DAT scanning in a University Hospital practice – is there unnecessary utilisation of DAT scanning when…
  • 2019 International Congress

    Art du Deplacement (ADD)/Parkour therapy for people with Parkinson’s disease (PDP)

    M. Schwed, T. Getrost, K. Torchia, G. Yao (Pfungstadt, Germany)

    Objective: The purpose of this study was to transfer ADD training methods into safe training paradigms for PDP, and psychologically framed coping strategies for mood…
  • 2019 International Congress

    The Clinical Features of Parkinson’s Disease with 20 Years or More Survival

    JJ. Lin, KC. Yueh (Nantou, Taiwan)

    Objective: To evaluate the clinical demographic data in Parkinson’s disease (PD) survivors with 20 years duration and beyond (PD-20) and investigate the impact of age…
  • 2019 International Congress

    Lack of Notable Skin Reactions from a Novel Levodopa/Carbidopa Prodrug after 10 Days of Repeated 24-Hour Continuous Subcutaneous Infusion at the Same Administration Site

    M. Facheris, X. Qi, C. Locke, M. Rosebraugh, J. Benesh (North Chicago, IL, USA)

    Objective: To assess the skin safety and tolerability of 24-hour continuous subcutaneous infusion (CSCI) of ABBV-951. Background: Therapeutic approaches for advanced Parkinson’s disease (aPD) patients…
  • 2019 International Congress

    OPICAPONE: REAL WORLD EVIDENCE IN TOLEDO´S MOVEMENT DISORDERS UNIT

    JC. Segundo-Rodríguez, N. López-Ariztegui, MI. Morales-Casado, N. García-Alvarado, A. Avila-Fernández, J. Pérez-Matos (Toledo, Spain)

    Objective: We present a prospective observational-real life study about the use in Movement Disorders Unit´s patients, since its commercialization in Spain (June 2017). Background: The…
  • « Previous Page
  • 1
  • …
  • 180
  • 181
  • 182
  • 183
  • 184
  • …
  • 388
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • DaTscan in clinical evaluation of Multiple System Atrophy
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley